Institutional shares held 161 Million
260K calls
620K puts
Total value of holdings $6.97B
$11.3M calls
$26.8M puts
Market Cap $3.86B
87,697,600 Shares Out.
Institutional ownership 183.54%
# of Institutions 266


Latest Institutional Activity in RVMD

Top Purchases

Q3 2024
Lord, Abbett & Co. LLC Shares Held: 1.83M ($80.7M)
Q3 2024
Farallon Capital Management LLC Shares Held: 11.3M ($499M)
Q3 2024
Janus Henderson Group PLC Shares Held: 6.14M ($270M)
Q3 2024
Jpmorgan Chase & CO Shares Held: 4.14M ($182M)
Q3 2024
Goldman Sachs Group Inc Shares Held: 2.35M ($104M)

Top Sells

Q3 2024
Bvf Inc Shares Held: 3.48M ($153M)
Q3 2024
Wellington Management Group LLP Shares Held: 11.4M ($502M)
Q3 2024
Alphabet Inc. Shares Held: 4.26M ($188M)
Q3 2024
Balyasny Asset Management LLC Shares Held: 1.65M ($72.8M)
Q3 2024
Morgan Stanley Shares Held: 653K ($28.8M)

About RVMD

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.


Insider Transactions at RVMD

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
1.93M Shares
From 20 Insiders
Grant, award, or other acquisition 205K shares
Open market or private purchase 1.3M shares
Exercise of conversion of derivative security 425K shares
Sell / Disposition
645K Shares
From 10 Insiders
Grant, award, or other acquisition 90K shares
Open market or private sale 553K shares
Sale (or disposition) back to the issuer 1.81K shares

Track Institutional and Insider Activities on RVMD

Follow Revolution Medicines, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RVMD shares.

Notify only if

Insider Trading

Get notified when an Revolution Medicines, Inc. insider buys or sells RVMD shares.

Notify only if

News

Receive news related to Revolution Medicines, Inc.

Track Activities on RVMD